EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT BURKITT/BURKITT-LIKE LYMPHOMA: A SYSTEMATIC REVIEW.

Autor:	Joshi U; Department of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA., Subedi R; Department of Internal Medicine, Unity Hospital - Rochester Regional Health, Rochester, NY 14626, USA., Nepal G; Department of Internal Medicine, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu 44600, Nepal., Gyawali S; Department of Internal Medicine, Sukraraj Tropical and Infectious Disease Hospital, Kathmandu 44600, Nepal., Agrawal V; Department of Internal Medicine, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu 44600, Nepal., Poudyal BS; Clinical Hematology and Bone Marrow Transplant Unit, Civil Service Hospital, Kathmandu 44600, Nepal., Bhatt VR; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA.; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA., D'Angelo CR; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA.; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Jazyk:	angličtina
Zdroj:	Experimental oncology [Exp Oncol] 2022 Nov; Vol. 44 (3), pp. 190-197.
DOI:	10.32471/exp-oncology.2312-8852.vol-44-no-3.18599
Abstrakt:	Background: Burkitt and Burkitt like lymphoma (BL/BLL) are highly proliferative germinal or post-germinal B cell tumors. Few studies have evaluated the impact of autologous stem cell transplantation (ASCT) on disease outcomes. Aim: We performed a systematic review to analyze the efficacy of ASCT as frontline consolidation and for treatment of relapsed/refractory cases in adult BL/BLL. Materials and Methods: Eligible studies with clear outcome measures on the efficacy of ASCT in adult patients with BL/BLL were identified through systematic search. The overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), and progression/relapse were used to assess the efficacy. Results: For patients who underwent ASCT in first CR, 5-year PFS and OS ranged between 70-78% and 70-83% respectively. For relapsed/refractory disease, 5-year PFS and OS were 27% and 31%, respectively. Patients undergoing ASCT for chemoresistant disease fared poorly with 3-year OS of 7% vs 37% for chemosensitive disease (p ≤ 0.00001). The overall response rate to ASCT for patients transplanted in first CR ranged between 71% and 93% and was 37% for patients who were transplanted in disease status other than first CR. Disease progression/relapse was observed in 16-29% of the patients transplanted in first CR, and 55% to 60% in relapsed disease. Conclusion: We found insufficient evidence to support ASCT over chemotherapy alone in the first remission for adult BL/BLL. Evidence supports guidelines recommending ASCT for chemosensitive disease but suggests there is no benefit to ASCT for chemoresistant disease.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu